TY - JOUR
T1 - Bioinspired mycobacterial lipid coating of porous particles for enhanced antimicrobial efficacy
AU - Pacheco, Jesus E. Campos
AU - Davids, Camilla
AU - Yalovenko, Tetiana
AU - Nasstrom, Elin
AU - Ahnlund, Maria
AU - Godaly, Gabriela
AU - Valetti, Sabrina
PY - 2025
Y1 - 2025
N2 - The study aimed to investigate the unique lipid composition of Mycobacterium bovis BCG and its potential to enhance antimicrobial efficacy of lipid-coated mesoporous silica particles (MSPs). The bacterial lipids (BL) were extracted with petroleum ether and analyzed via LC-MS, revealing a complex mixture of phospholipids, including cardiolipin, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerols. Lipid coating (using bacterial lipids and lung surfactant DPPC as the main component) was performed on MSPs via vesicle fusion approach and confirmed with ATR-FTIR spectroscopy. MSPs were loaded with clofazimine (CLZ), as a drug model for tuberculosis. The obtained BL-DPPC-coated CLZ-MSPs were more effective in inhibiting mycobacterial growth and killing intracellular mycobacteria compared to uncoated and DPPC-coated CLZ-MSPs. The bacterial lipids showed a good safety profile on M1-like and M2-like human primary macrophages without inducing a strong immune response or formation of foam cells. These findings suggest that the obtained bacterial lipid coatings can improve antimicrobial efficacy in treating both extracellular and intracellular mycobacteria infections directly in the lungs.
AB - The study aimed to investigate the unique lipid composition of Mycobacterium bovis BCG and its potential to enhance antimicrobial efficacy of lipid-coated mesoporous silica particles (MSPs). The bacterial lipids (BL) were extracted with petroleum ether and analyzed via LC-MS, revealing a complex mixture of phospholipids, including cardiolipin, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerols. Lipid coating (using bacterial lipids and lung surfactant DPPC as the main component) was performed on MSPs via vesicle fusion approach and confirmed with ATR-FTIR spectroscopy. MSPs were loaded with clofazimine (CLZ), as a drug model for tuberculosis. The obtained BL-DPPC-coated CLZ-MSPs were more effective in inhibiting mycobacterial growth and killing intracellular mycobacteria compared to uncoated and DPPC-coated CLZ-MSPs. The bacterial lipids showed a good safety profile on M1-like and M2-like human primary macrophages without inducing a strong immune response or formation of foam cells. These findings suggest that the obtained bacterial lipid coatings can improve antimicrobial efficacy in treating both extracellular and intracellular mycobacteria infections directly in the lungs.
KW - Bacterial lipids
KW - Cardiolipin
KW - Clofazimine (CLZ)
KW - Lipid coating
KW - Mesoporous silica particles (MSPs)
KW - Mycobacterial infections
KW - Mycobacterium bovis BCG
KW - Bacterial lipids
KW - Cardiolipin
KW - Clofazimine (CLZ)
KW - Lipid coating
KW - Mesoporous silica particles (MSPs)
KW - Mycobacterial infections
KW - Mycobacterium bovis BCG
UR - https://res.slu.se/id/publ/146650
U2 - 10.1016/j.ejps.2025.107225
DO - 10.1016/j.ejps.2025.107225
M3 - Journal article
C2 - 40780537
SN - 0928-0987
VL - 213
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
M1 - 107225
ER -